SCHEMBL25816442

SCHEMBL25816442

Nc1ccc(C2CCON2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.43
DRD3 P35462 4/20 0.43
DRD4 P21917 1/20 0.36
NOS3 P29474 1/20 0.34
NOS2 P35228 1/20 0.34
NNMT P40261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TNKS O95271 1/20 0.33
MAP4K4 O95819 1/20 0.32
CHRNB2 P17787 2/20 0.31
CHRNA4 P43681 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA7 P36544 1/20 0.31
MKNK1 Q9BUB5 1/20 0.31
MKNK2 Q9HBH9 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30338680 0.86 GABRP (0.36) DRD2DRD3NNMTSMN1; SMN2TNKS
SCHEMBL29641343 0.79 TNKS (0.34) TNKSCHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL18921312 0.79 CHRNB2 (0.31) CHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL29966900 0.79 CHRNB2 (0.31) CHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL18921319 0.79 CHRNB2 (0.31) CHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL29966490 0.79 CHRNB2 (0.31) CHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL18921404 0.79 TNKS (0.34) TNKSCHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL22256508 0.79 TNKS (0.34) TNKSCHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL22444813 0.79 TNKS (0.34) TNKSCHRNB2CHRNA4CHRNA3CHRNA7
SCHEMBL29966596 0.79 TNKS (0.34) TNKSCHRNB2CHRNA4CHRNA3CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 DRD2 2632/4885DRD3 3307/4885DRD4 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.